HAEM4:Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable: Difference between revisions
Bailey.Glen (talk | contribs) Created page with "==Primary Author(s)*== Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia __TOC__ ==Cancer Category/Type== Myelodysplastic/Myeloproliferative N..." |
Bailey.Glen (talk | contribs) No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable}} | |||
<blockquote class='blockedit'>{{Box-round|title=PREVIOUS EDITION|This page from the 4th edition of Haematolymphoid Tumours is being updated. See 5th edition [[HAEM5:Table_of_Contents|Table of Contents]]. | |||
}}</blockquote> | |||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
Ruth MacKinnon PhD | Ruth MacKinnon PhD | ||
| Line 31: | Line 36: | ||
When an underlying MPN has not been identified, the category of MDS/MPN-U is appropriate. <ref name=":0" /> | When an underlying MPN has not been identified, the category of MDS/MPN-U is appropriate. <ref name=":0" /> | ||
Cases with features of MDS/MPN-U may arise due to prior exposure to treatment and are included in the [[ | Cases with features of MDS/MPN-U may arise due to prior exposure to treatment and are included in the [[HAEM5:Myeloid neoplasm post cytotoxic therapy|Therapy-related myeloid neoplasms]] (t-MN). | ||
Well-defined MPN which subsequently develop dysplastic features and progress to a more aggressive phase are excluded from this category. | Well-defined MPN which subsequently develop dysplastic features and progress to a more aggressive phase are excluded from this category. | ||
| Line 51: | Line 56: | ||
==Clinical Features== | ==Clinical Features== | ||
*Overlap with [[Myelodysplastic Syndromes (MDS)|MDS]] and [[Myeloproliferative Neoplasms (MPN)|MPN]] <ref name=":0" /> | *Overlap with [[HAEM4:Myelodysplastic Syndromes (MDS)|MDS]] and [[HAEM4:Myeloproliferative Neoplasms (MPN)|MPN]] <ref name=":0" /> | ||
*Clinically the most heterogeneous of the MDS/MPN <ref name=":3" /> | *Clinically the most heterogeneous of the MDS/MPN <ref name=":3" /> | ||
*Does not have features that define it as belonging to any of the other categories of MDS/MPN <ref name=":0" /><ref name=":1" /> | *Does not have features that define it as belonging to any of the other categories of MDS/MPN <ref name=":0" /><ref name=":1" /> | ||
| Line 84: | Line 89: | ||
==Immunophenotype== | ==Immunophenotype== | ||
May be similar to that of [[Myelodysplastic Syndromes (MDS)|MDS]] or [[Myeloproliferative Neoplasms (MPN)|MPN]] <ref name=":0" /> | May be similar to that of [[HAEM4:Myelodysplastic Syndromes (MDS)|MDS]] or [[HAEM4:Myeloproliferative Neoplasms (MPN)|MPN]] <ref name=":0" /> | ||
==Chromosomal Rearrangements (Gene Fusions)== | ==Chromosomal Rearrangements (Gene Fusions)== | ||
| Line 212: | Line 217: | ||
==Notes== | ==Notes== | ||
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. | <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. | ||
[[Category:HAEM4]] [[Category:DISEASE]] | |||